Baird lowered the firm’s price target on DexCom (DXCM) to $80 from $87 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results showing solid start to the year with growth catalysts looming.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom price target lowered to $75 from $90 at Mizuho
- DexCom price target lowered to $81 from $83 at Raymond James
- DexCom price target raised to $100 from $95 at Canaccord
- DexCom price target lowered to $67 from $72 at Barclays
- Buy Rating Reaffirmed on Dexcom as Margin Strength and Global Patient Growth Offset U.S. CGM Concerns; Price Target Reset to $75